Qualigen Therapeutics, Inc.
QLGN
$3.01
-$0.03-0.99%
| Weiss Ratings | QLGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | QLGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | QLGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.16 | |||
| Price History | QLGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.90% | |||
| 30-Day Total Return | -3.53% | |||
| 60-Day Total Return | -22.82% | |||
| 90-Day Total Return | -42.67% | |||
| Year to Date Total Return | -28.36% | |||
| 1-Year Total Return | -85.13% | |||
| 2-Year Total Return | -94.16% | |||
| 3-Year Total Return | -98.91% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -89.67% | |||
| 52-Week Low % Change | 2.70% | |||
| Price | QLGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $29.44 | |||
| 52-Week Low Price | $2.96 | |||
| 52-Week Low Price (Date) | Jan 29, 2025 | |||
| 52-Week High Price (Date) | Jul 12, 2024 | |||
| Valuation | QLGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.24M | |||
| Enterprise Value | 3.28M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -56.15 | |||
| Earnings Per Share Growth | -69.64% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -0.78 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $3.01 | |||
| Enterprise Value/EBITDA (TTM) | -0.49 | |||
| Enterprise Value/EBIT | -0.49 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | QLGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 387.90K | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | QLGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 760 452 8111 | |||
| Address | 5857 Owens Avenue Carlsbad, CA 92008 | |||
| Website | www.qlgntx.com | |||
| Country | United States | |||
| Year Founded | 1996 | |||
| Profitability | QLGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | QLGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -126.43% | |||
| Return on Equity | -- | |||
| Income Statement | QLGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -2.55M | |||
| EBITDA (TTM) | -6.70M | |||
| EBIT (TTM) | -6.71M | |||
| Net Income (TTM) | -7.85M | |||
| Net Income Avl. to Common (TTM) | -7.85M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 44.54% | |||
| EPS Diluted (TTM) | -56.15 | |||
| EPS Diluted Growth (Q YOY) | 87.02% | |||
| Balance Sheet | QLGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 388.20K | |||
| Cash Per Share (Q) | $1.00 | |||
| Total Current Assets (Q) | 2.31M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -2.14M | |||
| Current Ratio (Q) | 0.519 | |||
| Book Value Per Share (Q) | -$3.90 | |||
| Total Assets (Q) | 2.31M | |||
| Total Current Liabilities (Q) | 4.45M | |||
| Total Debt (Q) | 1.43M | |||
| Total Liabilities (Q) | 4.45M | |||
| Total Common Equity (Q) | -2.14M | |||
| Cash Flow | QLGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -664.60K | |||
| Cash from Financing (TTM) | 4.83M | |||
| Net Change in Cash (TTM) | -5.56M | |||
| Levered Free Cash Flow (TTM) | -6.57M | |||
| Cash from Operations (TTM) | -9.73M | |||
